The authors reply [5]

New England Journal of Medicine

Volumn 354, Issue 3, 2006, Pages 300-

  Lieberman, Jeffrey A ^a   Stroup, T Scott ^b   Davis, Sonia M ^c  

^a College of Physicians and Surgeons ^*  (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PERPHENAZINE; QUETIAPINE; ZIPRASIDONE;

DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LETTER; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; WEIGHT GAIN;

EID: 30944468756     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc052903     Document Type: Letter

References (1)

1. Bang H, Ni L, Davis CE. Assessment of blinding in clinical trials. Control Clin Trials 2004;25:143-56.